Hormonal receptor-positive, HER2-positive breast cancers, which constitute 5% of all breast cancers, also exhibit high degrees of heterogeneity in ER and HER2 expression which has been shown to be associated with their response to neoadjuvant chemotherapy and HER2-targeted therapy [36]. The gene discussed is ERBB2; the disease is breast carcinoma.